Ignite Creation Date:
2024-05-06 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 1:55 PM
Study NCT ID:
NCT04723914
Status:
UNKNOWN
Last Update Posted:
2021-01-26
First Post:
2021-01-21
Brief Title:
Dual Target CAR-T Cells in B-cell Lymphoma
Sponsor:
YuLi
Organization:
Shenzhen University General Hospital
Study Overview
Official Title:
Clinical Trial of CD19CD20 Dual Target CAR-T Cells in the Treatment of RelapsedRefractory B-cell Lymphoma
Status:
UNKNOWN
Status Verified Date:
2020-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CAR-T
Brief Summary:
Prospectively evaluate the safety and effectiveness of CD19CD20 dual-target CAR-T cells in the treatment of relapsedrefractory B-cell lymphoma
Detailed Description:
Prospectively evaluate the safety and effectiveness of CD19CD20 dual-target CAR-T cells in the treatment of relapsedrefractory B-cell lymphoma Strictly follow the inclusion criteria to screen eligible subjects for inclusion in clinical trials The selected patients received CD19CD20 dual-target CAR-T cell therapy After the treatment is over follow-up regularly to determine the survival status and follow-up treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None